Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.95%488.44B | 15.14%2.13T | 9.59%444.23B | 7.17%1.85T | 17.18%620.22B | 5.30%459.73B | -11.09%364B | 15.70%405.34B | 14.97%1.73T | 14.51%529.28B |
| Cost of revenue | 10.54%396.63B | 10.46%1.7T | 5.77%358.81B | 10.44%1.54T | 12.77%498.75B | 8.35%357.37B | 4.59%341.68B | 15.80%339.25B | 11.56%1.39T | 11.02%442.29B |
| Gross profit | 7.48%91.81B | 38.21%431.54B | 29.24%85.42B | -6.47%312.24B | 39.63%121.47B | -4.11%102.35B | -73.01%22.32B | 15.20%66.09B | 31.81%333.82B | 36.36%86.99B |
| Operating expense | 4.27%77.47B | 12.33%311.59B | 19.97%74.3B | 8.88%277.39B | -4.34%81.22B | 14.69%68.37B | 15.86%65.87B | 15.96%61.93B | 22.21%254.78B | 34.88%84.9B |
| Selling and administrative expenses | 4.16%76.92B | 11.20%306.96B | 18.43%73.84B | 9.41%276.04B | -4.38%79.85B | 15.28%67.96B | 17.06%65.89B | 16.40%62.35B | 19.50%252.31B | 33.07%83.5B |
| -General and administrative expense | 4.16%76.92B | 11.20%306.96B | 18.43%73.84B | 9.41%276.04B | -4.38%79.85B | 15.28%67.96B | 17.06%65.89B | 16.40%62.35B | 19.50%252.31B | 33.07%83.5B |
| Other operating expenses | 30.19%1.88B | 9.49%7.72B | 84.42%1.44B | -3.65%7.05B | -0.29%3.42B | 31.74%1.37B | 7.04%1.48B | -46.63%783M | 76.51%7.32B | 162.23%3.43B |
| Total other operating income | 34.69%1.32B | -45.69%3.1B | -18.29%983M | 17.61%5.7B | 0.84%2.05B | 153.30%960M | 83.62%1.49B | -25.97%1.2B | -28.62%4.85B | 82.57%2.03B |
| Operating profit | 28.98%14.34B | 244.25%119.95B | 167.15%11.12B | -55.92%34.84B | 1,824.04%40.25B | -27.89%33.98B | -268.36%-43.55B | 5.02%4.16B | 76.52%79.04B | 145.54%2.09B |
| Net non-operating interest income (expenses) | -141.23%-3.69B | -150.37%-35.61B | 89.90%8.95B | -18.45%-14.22B | 237.03%4.45B | -22.89%-17.05B | -607.25%-6.34B | -21.61%4.71B | -345.49%-12.01B | -354.03%-3.25B |
| Non-operating interest income | -95.58%606M | 12.60%3.42B | 74.46%13.71B | 32.69%3.04B | 0.54%933M | ---- | ---- | 4.62%7.86B | -10.37%2.29B | -41.56%928M |
| Non-operating interest expense | -9.77%4.3B | 126.11%39.03B | 51.34%4.76B | 20.73%17.26B | -184.25%-3.52B | 22.89%17.05B | 217.48%6.34B | 109.73%3.15B | 172.27%14.3B | 1,251.78%4.18B |
| Net investment income | ||||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | 6.17%6.18B | 104.03%23.17B | -4.50%5.82B | 242.73%11.36B | 938.97%5.21B | -113.34%-391M | 20.49%447M | 865.61%6.09B | 123.00%3.31B | -180.75%-621M |
| Special income (charges) | ||||||||||
| Other non-operating income (expenses) | ||||||||||
| Income before tax | -35.00%16.82B | 236.20%107.52B | 72.96%25.89B | -54.54%31.98B | 2,907.14%49.91B | -54.28%16.54B | -295.09%-49.44B | 41.12%14.97B | 154.24%70.35B | -161.33%-1.78B |
| Income tax | -4.44%9.5B | 268.09%17.19B | 80.14%9.94B | -68.99%4.67B | 422.21%10.77B | -13.37%5.97B | -362.31%-17.58B | 14.74%5.52B | 17.33%15.06B | -420.94%-3.34B |
| Net income | -54.07%7.32B | 230.75%90.33B | 68.75%15.94B | -50.61%27.31B | 2,404.48%39.15B | -63.90%10.57B | -270.92%-31.86B | 63.05%9.45B | 272.67%55.29B | -15.92%1.56B |
| Net income continuous operations | -54.07%7.32B | 230.75%90.33B | 68.75%15.94B | -50.61%27.31B | 2,404.48%39.15B | -63.90%10.57B | -270.92%-31.86B | 63.05%9.45B | 272.67%55.29B | -15.92%1.56B |
| Noncontrolling interests | 443.64%3.08B | 20.39%2.33B | 58.54%566M | -14.55%1.93B | -72.49%288M | 30.15%708M | 73.57%578M | 6.25%357M | 2.87%2.26B | 122.77%1.05B |
| Net income attributable to the company | -72.40%4.24B | 246.77%88B | 69.16%15.38B | -52.15%25.38B | 7,415.86%38.86B | -65.68%9.87B | -277.20%-32.44B | 66.56%9.09B | 319.60%53.03B | -62.78%517M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -72.40%4.24B | 246.77%88B | 69.16%15.38B | -52.15%25.38B | 7,415.86%38.86B | -65.68%9.87B | -277.20%-32.44B | 66.56%9.09B | 319.60%53.03B | -62.78%517M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -72.34%25.39 | 246.80%525.44 | 69.14%91.79 | -52.15%151.51 | 7,432.14%231.99 | -65.69%58.9 | -277.18%-193.66 | 66.57%54.27 | 319.32%316.63 | -62.85%3.08 |
| Diluted earnings per share | -72.34%25.39 | 246.80%525.44 | 69.14%91.79 | -52.15%151.51 | 7,431.81%231.9797 | -65.69%58.9 | -277.18%-193.66 | 66.57%54.27 | 319.32%316.63 | -62.85%3.08 |
| Dividend per share | 0 | 200.00%150 | 0 | -44.44%50 | -50.00%30 | 0 | -33.33%20 | 0 | 125.00%90 | 200.00%60 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |